Literature DB >> 29207123

NACHT, LRR and PYD domains-containing protein 3 inflammasome is activated and inhibited by berberine via toll-like receptor 4/myeloid differentiation primary response gene 88/nuclear factor-κB pathway, in phorbol 12-myristate 13-acetate-induced macrophages.

Zhouqing Huang1, Bozhi Ye1, Jibo Han1, Fanqi Kong1, Peiren Shan1, Zhongqiu Lu2, Zhouqing Huang1, Weijian Huang1.   

Abstract

The nucleotide-binding domain, leucine-rich-containing family, pyrin domain-containing-3 (NLRP-3) inflammasome has recently emerged as a pivotal regulator of chronic inflammation. The present study investigated the expression of NLRP3 inflammasome in phorbol 12-myristate 13-acetate (PMA)-induced macrophages, and aimed to identify the effects of berberine on the inflammasome. Human monocytic THP-1 cells were pretreated with berberine for 1 h and then induced with PMA for 48 h. Total RNA and protein were collected for reverse transcription-quantitative polymerase chain reaction and western blot analysis, respectively. Supernatants were collected to determine IL-1β levels by using ELISA. The present study demonstrated that NLRP3 inflammasome and IL-1β were activated in PMA-induced macrophages in a time-dependent manner, whereas berberine significantly inhibited their expression in a dose-dependent manner in PMA-induced macrophages. Furthermore, berberine also suppressed the toll-like receptor 4 (TLR4)/myeloid differentiation primary response gene 88 (Myd88)/nuclear factor (NF)-κB signaling pathway which was activated during the conversion of THP-1 cells to macrophages by PMA. In conclusion, berberine reduced NLRP3 inflammasone expression by suppressing the activation of the TLR4/Myd88/NF-κB signaling pathway in PMA-induced macrophages. This inhibitory effect may imply an important role of berberine on chronic inflammation and atherogenic progression in coronary artery disease.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 29207123     DOI: 10.3892/mmr.2017.8189

Source DB:  PubMed          Journal:  Mol Med Rep        ISSN: 1791-2997            Impact factor:   2.952


  6 in total

1.  Effect of Berberine on Activation of TLR4-NFκB Signaling Pathway and NLRP3 Inflammasome in Patients with Goat.

Authors:  Wan-Tai Dang; Dan Xu; Jing-Guo Zhou
Journal:  Chin J Integr Med       Date:  2022-09-20       Impact factor: 2.626

Review 2.  Berberine in Cardiovascular and Metabolic Diseases: From Mechanisms to Therapeutics.

Authors:  Xiaojun Feng; Antoni Sureda; Samineh Jafari; Zahra Memariani; Devesh Tewari; Giuseppe Annunziata; Luigi Barrea; Sherif T S Hassan; Karel Šmejkal; Milan Malaník; Alice Sychrová; Davide Barreca; Lovro Ziberna; Mohamad Fawzi Mahomoodally; Gokhan Zengin; Suowen Xu; Seyed Mohammad Nabavi; Ai-Zong Shen
Journal:  Theranostics       Date:  2019-03-16       Impact factor: 11.556

Review 3.  Inhibitory Role of Berberine, an Isoquinoline Alkaloid, on NLRP3 Inflammasome Activation for the Treatment of Inflammatory Diseases.

Authors:  Paromita Sarbadhikary; Blassan P George; Heidi Abrahamse
Journal:  Molecules       Date:  2021-10-15       Impact factor: 4.411

Review 4.  Cytokine storm-calming property of the isoquinoline alkaloids in Coptis chinensis Franch.

Authors:  Yuejia Lan; Huan Wang; Jiasi Wu; Xianli Meng
Journal:  Front Pharmacol       Date:  2022-09-06       Impact factor: 5.988

Review 5.  Immunomodulatory Effects of Diterpenes and Their Derivatives Through NLRP3 Inflammasome Pathway: A Review.

Authors:  Muhammad Torequl Islam; Sanaa K Bardaweel; Mohammad S Mubarak; Wojciech Koch; Katarzyna Gaweł-Beben; Beata Antosiewicz; Javad Sharifi-Rad
Journal:  Front Immunol       Date:  2020-09-25       Impact factor: 7.561

6.  A Systems Biology Workflow for Drug and Vaccine Repurposing: Identifying Small-Molecule BCG Mimics to Reduce or Prevent COVID-19 Mortality.

Authors:  Rima Hajjo; Alexander Tropsha
Journal:  Pharm Res       Date:  2020-10-06       Impact factor: 4.200

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.